首页>
外国专利>
COMBINATION OF SOMATOSTATIN ANALOGUES WITH DOPAMINE RECEPTOR OR GROWTH HORMONE RECEPTOR ANTAGONIST
COMBINATION OF SOMATOSTATIN ANALOGUES WITH DOPAMINE RECEPTOR OR GROWTH HORMONE RECEPTOR ANTAGONIST
展开▼
机译:生长抑素类似物与多巴胺受体或生长激素受体拮抗剂的组合
展开▼
页面导航
摘要
著录项
相似文献
摘要
1. A combination containing (a) sandostatin® LAR® and (b) a second active compound selected from the group consisting of a dopamine agonist and growth hormone receptor antagonist, in the form of a combined preparation for simultaneous, separate or sequential administration in the treatment of acromegaly, wherein said Sandostatin® LAR® is administered at a dose of 40 mg / 28 days. ! 2. The combination according to claim 1, characterized in that said combination preparation is used to treat patients with acromegaly who do not observe normalization of biochemical markers after treatment for at least 6 months using at least one somatostatin analogue during the standard course of treatment. ! 3. The combination according to claim 2, characterized in that during the specified standard course of treatment, 30 mg of Sandostatin® LAR® is administered every 28 days. ! 4. The combination according to claim 3, characterized in that said combination preparation is administered for at least 4 months. ! 5. The combination according to claim 4, characterized in that a dose of 40 mg of said sandostatin® LAR® is administered by two injections of 20 mg each. ! 6. The combination according to claim 5, characterized in that said sandostatin® LAR® is administered by intramuscular injection. ! 7. The combination according to claim 1, characterized in that said second active compound is a dopamine agonist. ! 8. The combination according to claim 7, characterized in that said dopamine agonist is cabergoline. ! 9. The combination of claim 8, wherein the dose of said cabergoline is 0.5-3.5 mg per week. ! 10. The combination according to claim 9, characterized in that the specified dose of cabergoline is! during the first week of treatment 0.5 mg,! during the second week of treatment
展开▼